Announcement of The Consolidated Financial Report for The 1st Quarter of 2026

2026.5.6

Provided by: TTY BIOPHARM COMPANY LIMITED

SEQ_NO	1	Date of announcement	2026/05/06	Time of announcement	17:14:45
Subject	Announcement of The Consolidated Financial Report for The 1st Quarter of 2026
Date of events	2026/05/06	To which item it meets	paragraph 31
Statement	1.Date of the board of directors submitted or approved:2026/05/06 2.Date of the audit committee approved:2026/05/06 3.Start and end dates of financial reports or unaudited financial information of the reporting period:2026/01/01~2026/03/31 4.Operating revenue accumulated from 1/1 to end of the period (thousand NTD):1,520,487 5.Gross profit (loss) from operations accumulated from 1/1 to end of the period (thousand NTD):916,294 6.Net operating income (loss) accumulated from 1/1 to end of the period (thousand NTD):489,470 7.Profit (loss) before tax accumulated from 1/1 to end of the period (thousand NTD):573,619 8.Profit (loss) accumulated from 1/1 to end of the period (thousand NTD):463,157 9.Profit (loss) during the period attributable to owners of parent accumulated from 1/1 to end of the period (thousand NTD):443,065 10.Basic earnings (loss) per share accumulated from 1/1 to end of the period (NTD):1.78 11.Total assets end of the period (thousand NTD):11,675,866 12.Total liabilities end of the period (thousand NTD):4,277,189 13.Equity attributable to owners of parent end of the period (thousand NTD):6,568,346 14.Any other matters that need to be specified:None.